Profiles of Phase IV Investigators and Subsequent Prescribing of the Study Drug

H. Glass, D. W. Dalton
{"title":"Profiles of Phase IV Investigators and Subsequent Prescribing of the Study Drug","authors":"H. Glass, D. W. Dalton","doi":"10.3109/J058V17N03_02","DOIUrl":null,"url":null,"abstract":"ABSTRACTThis study examines the demographic and prescribing characteristics of Phase IV clinical investigators who subsequently increase their prescribing level of the study drug. The study also examines whether the amount of the grant payment the investigator receives from the pharmaceutical company to participate in a Phase IV study influences that investigator's subsequent prescribing levels of the study drug. The study found that certain characteristics of the physicians and their practices are associated with increased prescribing levels of the study drug, these characteristics being: younger physicians; physicians who already write a higher percentage of their drugs from the company sponsoring the clinical trial; physicians who are participating in clinical trials of larger pharmaceutical companies; and doctors who write a higher volume of drugs in the drug class of the study drug but who actually write relatively fewer pre-study prescriptions of the study drug itself. However, the relative grant am...","PeriodicalId":16734,"journal":{"name":"Journal of Pharmaceutical Marketing & Management","volume":"28 1","pages":"3-17"},"PeriodicalIF":0.0000,"publicationDate":"2006-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"7","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Pharmaceutical Marketing & Management","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3109/J058V17N03_02","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 7

Abstract

ABSTRACTThis study examines the demographic and prescribing characteristics of Phase IV clinical investigators who subsequently increase their prescribing level of the study drug. The study also examines whether the amount of the grant payment the investigator receives from the pharmaceutical company to participate in a Phase IV study influences that investigator's subsequent prescribing levels of the study drug. The study found that certain characteristics of the physicians and their practices are associated with increased prescribing levels of the study drug, these characteristics being: younger physicians; physicians who already write a higher percentage of their drugs from the company sponsoring the clinical trial; physicians who are participating in clinical trials of larger pharmaceutical companies; and doctors who write a higher volume of drugs in the drug class of the study drug but who actually write relatively fewer pre-study prescriptions of the study drug itself. However, the relative grant am...
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
IV期研究人员概况和研究药物的后续处方
摘要本研究考察了随后增加研究药物处方水平的IV期临床研究者的人口学特征和处方特征。该研究还考察了研究者从制药公司获得的参与IV期研究的资助金额是否会影响研究者随后对研究药物的处方水平。研究发现,医生的某些特征和他们的实践与研究药物处方水平的增加有关,这些特征是:年轻的医生;已经从赞助临床试验的公司开出较高比例药物的医生;参与大型制药公司临床试验的医生;医生在研究药物类别中开了大量的药物但实际上他们在研究前开的研究药物本身的处方相对较少。然而,相对的补助金是……
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Developing a Managed Care Customer Focus Rx-to-OTC The Prescription to Nonprescription Switch The Relationship Between the Consumer and the Health Care System Pharmacists' Opinions About Pharmaceutical Manufacturers
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1